CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$2.91
-0.08 (-2.68%)
Open$3.00
Previous Close$2.99
Day High$3.04
Day Low$2.83
52W High$6.16
52W Low$1.96
Volume—
Avg Volume1.03M
Market Cap342.14M
P/E Ratio—
EPS$-1.40
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+575.9% upside
Current
$2.91
$2.91
Target
$19.67
$19.67
$12.33
$19.67 avg
$23.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.41M | 2.24M | 70.28M |
| Net Income | -164,261,790 | -234,995,407 | -10,926,196 |
| Profit Margin | -11,665.3% | -11,082.0% | -15.6% |
| EBITDA | -175,713,439 | -265,343,772 | -18,107,687 |
| Free Cash Flow | — | — | -6,087,830 |
| Rev Growth | -37.1% | -37.1% | +8.8% |
| Debt/Equity | 0.01 | 0.01 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |